

SEQUENCE LISTING

INS
A1

<110> Liao, Fang
Hicklin, Daniel
Bohlen, Peter

<120> Antibody Antagonists of VE-Cadherin Without Adverse Effects on
Vascular Permeability

<130> 11245/2

<140> filed herewith

<141> 2000-03-31

<160> 6

<170> WordPerfect 8.0 for Windows

<210> 1

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 1

Asp Glu Ile Trp Asn Gln Met His Ile Asp Glu Glu Lys Asn Glu
1 5 10 15

<210> 2

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 2

Asp Trp Ile Trp Asn Gln Met His Ile Asp Glu Glu Lys Asn Glu
1 5 10 15

<210> 3

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 3

Asp Trp Ile Trp Asn Gln Met His Ile Asp Glu Glu Lys Asn Thr
1 5 10 15

<210> 4

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 4

Tyr Val Lys Asp Gln Ser Asn Tyr Asn Arg Gln Asn Ala Lys Tyr Cys
1 5 10 15

<210> 5

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 5

Lys Tyr Val Leu Gln Gly Glu Phe Ala Gly Lys Ile Phe Gly Val Asp
1 5 10 15

Ala Cys

18

<210> 6

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 6

Leu Ile Val Asp Lys Asn Thr Asn Lys Asn Leu Glu Gln Pro Cys
1 5 10 15